Gapping down
In reaction to disappointing earnings/guidance: YOD -18%, MOV -16%, RTRX -13.9%, RCON -9.6%, BIOC -7.5%, SYMX -6.1%, VJET -6%, YOKU -5.9%, MNDL -5.5%, (Mandalay Digital to acquire Appia; name to change to Digital Turbine; MNDL stock to be issued at agreed-upon value of $4.50 per share; significant revenue synergy potential; immediate cost savings anticipated ), TSE -5.4%, WYY -5.1%, CREG -4.4%, SINA -4.1%, CVTI -3.9%, (commenced a public offering of 2.2 mln shares of its Class A common stock), FENG -2.3%, ELP -2.3%, AMAT -2.2%, CCS -1.8%, XON -1.6%
M&A news: AZN -2.7% (not likely to get revised bid from Pfizer (PFE), according to Reuters
Select Brazil related names showing weakness: SID -5.4%, BBD -4.2%, ITUB -3.9%, CIG -3.9%, ABEV -3%, TSU -2.6%, VALE -2.3%
Select metals/mining stocks trading lower: AU -3.1%, AUQ -3.1%, AEM 3.0%, EGO -2.6%, HMY -2.5%, GFI -2.4%, SLV -1.9%, IAG -1.1%, RIO -1.1%
Other news: ABGB -41.9% (disclosed clarification to misunderstanding around its calculation of corporate net debt), BAXS -33.3% (announced the termination of its Nasdaq listing), OCN -6.7% (co and Wells Fargo (WFC) agreed to cancel the sale of mortgage servicing rights), PBR -6.4% (failed to meet deadline to release earnings), ENLK -6.2% (announced the commencement of an underwritten public offering of 10.5 mln common units representing limited partner interests of the Partnership), NOK -4.4% (sets key 2015 and long-term financial targets, outlines operational and strategic priorities at its Capital Markets dayI), CVTI -4.1% (announced that it has commenced a public offering of 2.2 mln shares of its Class A common stock; co also reported earnings), CQH -3.2% (Cheniere Energy Partners announces public offering of 10 mln common shares), JRJC -2.7% (ceased its client-auditor relationship with its independent registered public accounting firm Grant Thornton China), PBYI -2.4% (announces positive top line results from PB272 Phase II trial in HER2 positive metastatic breast cancer (NEfERTT Trial); Neratinib achieves statistically significant reduction in incidence of central nervous system metastases ), ARCP -1.5% (receives lender waiver and extension for reporting Q3 financial statements)
Analyst comments: MTOR -2.5% (downgraded to Neutral from Buy at Goldman ), OLED -2.2% (downgraded to Perform at Oppenheimer ), LULU -1.5% (downgraded to Underperform from Neutral at Sterne Agee ), NKE -0.7% (downgraded to Neutral from Buy at Sterne Agee)